Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
74,361,296
-
Number of holders
-
60
-
Total 13F shares, excl. options
-
25,129,757
-
Shares change
-
-366,799
-
Total reported value, excl. options
-
$92,163,767
-
Value change
-
-$1,838,747
-
Number of buys
-
31
-
Number of sells
-
-21
-
Price
-
$3.67
Significant Holders of Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) as of Q4 2018
68 filings reported holding CRVS - Corvus Pharmaceuticals, Inc. - Common Stock as of Q4 2018.
Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) has 60 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 25,129,757 shares
of 74,361,296 outstanding shares and own 33.79% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (5,967,584 shares), Novo Holdings A/S (4,420,516 shares), ADAMS STREET PARTNERS LLC (3,275,616 shares), PRICE T ROWE ASSOCIATES INC /MD/ (1,986,163 shares), BVF INC/IL (1,890,507 shares), FMR LLC (1,041,256 shares), BlackRock Inc. (946,378 shares), RENAISSANCE TECHNOLOGIES LLC (662,300 shares), COWEN INC. (659,019 shares), and Rock Springs Capital Management LP (400,000 shares).
This table shows the top 60 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.